Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  imiquimod
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 31 for your search:
Start Over
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: HSC-MS-06-0478, OSP-24412, NCT00581425
Effect of Topical Imiquimod on Lentigo Maligna
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 45 and over
Sponsor: Other
Protocol IDs: LIMIT-1, NCT01161888
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GW01-1001, NCT01413763
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: X-03016-3284, 2010-022054-16, NCT01453179
Topical Imiquimod for Bowen's Disease of the Head and Neck
Phase: Phase III, Phase II
Type: Prevention, Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Other
Protocol IDs: C.2005.087, NCT00384124
ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: ITIC1.0, NCT00941252
Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 75090409, NCT01212562
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SYM 2012-01, NCT01686152
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STML-701-0114, NCT02078648
Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
Phase: Phase II
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069223, NCCTG-989251, NCI-P02-0208, NCT00031759
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 060069, 06-C-0069, NCI-06-C-0069, 7676, NCI-7676, NCI-P6703, NCT00304057, NCT00273910
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
Phase: Phase II
Type: Supportive care
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: Eudract number: 2006-004902-16, LREC number: 06/Q2201/143, NCT00596336
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CYT004-MelQbG10 04, NCT00651703
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 07-380, NCT00799110
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6578, NCI-2010-00040, R01CA138521, 131, UWCC-6578, FHCRC-6578, IR-6578, NCT00821964
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 09-0225, NCT00899574
Dendritic Cell Vaccine for Patients With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-000202, NCT01204684
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIMTOP-I, NCT01611480
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TMX-101-003, NCT01731652
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000355151, NCI-02-CC-0289, 3M-1454-IMIQ, NCT00079300
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 12 and over
Sponsor: NCI, Other
Protocol IDs: 11490, UVACC-MEL-45, UVACC-34204, UVACC-HIC-11490, NCT00118313
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 04-53, LUD2004-006, NCT00142454
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Phase: Phase I
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Other
Protocol IDs: 2008LS053, 0809M48641, NCT01171469
Start Over